Figure 3.

A. Concentration response curves elicited by cumulative application of U46619 in human cerebral arteries incubated for 48 h, human cerebral arteries incubated for 48 h with the MEK1/2 inhibitor U0126 (5 μM) and control human arteries. Data are expressed as mean ± s.e.m. B. Sections from the human cerebral artery showing TP receptor immunoreactivity in the smooth muscle cell layer. C. Expression of TP protein levels in human cerebral arteries incubated for 48 h with or without the MEK1/2 inhibitor U0126 (5 μM) and control human arteries. Data are expressed as percentage of fresh and given as mean ± s.e.m. *P<0.05, ** P<0.01.